WILMINGTON, DE, September 8, 2025 (GLOBE NEWSWIRE) -- Enovis™ (NYSE: ENOV), a global medical technology innovator, will showcase its portfolio of foot and ankle solutions at the American Orthopaedic Foot & Ankle Society (AOFAS) annual meeting in Savannah, GA., Sept. 10-13. Among the technologies displayed will be the new Pecaplasty® Wires First System for percutaneous bunion surgery.
“Pecaplasty® Wires First is a leap forward in MIS bunion surgery—helping surgeons achieve reproducible outcomes through an intuitive technique,” said Gary Justak, President and General Manager of Enovis™ Foot & Ankle. “Building on the legacy of Novastep®, this second-generation platform puts Enovis out in front of every first-gen product on the market. We tackled the most challenging step of the case to shorten the learning curve so surgeons adopt faster and patients benefit sooner through improved outcomes.”
Enovis has continued to advance the Pecaplasty® system since adding it to the company’s foot and ankle portfolio following the 2023 acquisition of Novastep®. "The wires first approach provides a simple and predictable modality for minimally invasive bunion correction that will change the game for surgeons,” said Dr. Amiethab Aiyer, M.D., a foot and ankle surgeon at Johns Hopkins University/School of Medicine, Department of Orthopaedics. “With wires first, both you and your patients win."
AOFAS attendees are encouraged to attend Wires 500, an exclusive surgeon-led event, for hands-on Pecaplasty Wires First demonstrations taking place Sept. 11 at Myrtle and Rose at the JW Marriott. Register here for an all-access pass to the fast lane of innovation.
Visit booth #312 to discover the Enovis foot and ankle portfolio, including products from the DynaNail® family powered by NiTiNOL, the Arsenal Foot™ Plating System, the new bone growth stimulator, Manafuse®, Aircast® AirSelect™ Elite, and other technologies designed to enhance patient outcomes and restore motion for life. For live updates during the conference, follow @enovisfootankle on Instagram and Enovis Foot & Ankle on LinkedIn.
About Enovis
Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.
*Dr. Aiyer is a paid consultant of Enovis.
Media Contact
Rachel Colloff
Director, Corporate Communications
Rachel.Colloff@enovis.com